These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 26364504)
21. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors. Trogrlic M; Tezak S Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of tricine and EDDA as Co-ligands for 99mTc-labeled HYNIC-MSH analogs for melanoma imaging. Garcia MF; Zhang X; Gallazzi F; Fernandez M; Moreno M; Gambini JP; Porcal W; Cabral P; Quinn TP Anticancer Agents Med Chem; 2015; 15(1):122-30. PubMed ID: 25175799 [TBL] [Abstract][Full Text] [Related]
23. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy. Garai I; Barna S; Nagy G; Forgacs A Nucl Med Rev Cent East Eur; 2016; 19(2):93-8. PubMed ID: 27479887 [TBL] [Abstract][Full Text] [Related]
24. Improved radiopharmaceutical based on 99mTc-Bombesin-folate for breast tumour imaging. Aranda-Lara L; Ferro-Flores G; Ramírez Fde M; Ocampo-García B; Santos-Cuevas C; Díaz-Nieto L; Isaac-Olivé K Nucl Med Commun; 2016 Apr; 37(4):377-86. PubMed ID: 26657220 [TBL] [Abstract][Full Text] [Related]
25. Preliminary application of micro-SPECT/CT imaging by Zhang Y; Meng L; Li B; Tan H; Lin QY; Cheng D; Shi H Chem Biol Drug Des; 2019 Apr; 93(4):447-453. PubMed ID: 30381892 [TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of standardized uptake values (SUV) of metastatic bone lesions in scintigraphy with [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide in patients with neuroendocrine tumours. Malarz MM; Birkenfeld B; Piwowarska-Bilska H Nucl Med Rev Cent East Eur; 2024; 27(0):31-35. PubMed ID: 39162352 [TBL] [Abstract][Full Text] [Related]
34. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors. Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172 [TBL] [Abstract][Full Text] [Related]
36. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Gabriel M; Decristoforo C; Maina T; Nock B; vonGuggenberg E; Cordopatis P; Moncayo R Cancer Biother Radiopharm; 2004 Feb; 19(1):73-9. PubMed ID: 15068614 [TBL] [Abstract][Full Text] [Related]
37. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET. Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418 [TBL] [Abstract][Full Text] [Related]
38. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920 [TBL] [Abstract][Full Text] [Related]
39. Formulation and Preclinical Testing of Tc-99m-Labeled HYNIC-Glc-FAPT as a FAP-Targeting Tumor Radiotracer. Yang X; Li G; Ruan C; Hu K; Tang G Bioconjug Chem; 2023 Nov; 34(11):2133-2143. PubMed ID: 37874952 [TBL] [Abstract][Full Text] [Related]
40. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]